AllRock Bio raises $50 million to drive therapy for pulmonary hypertension into phase 2 trials
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
Funding supports development of first-in-class pan-ROCK inhibitor ROC-101 through Phase 2a clinical testing
ProBioGen will oversee the design, construction, and operation of the 4,600-square-meter GMP manufacturing unit
Late-breaking data presented at WCLC highlight significant and sustained improvements in overall survival, including more than doubling five-year survival rates compared to chemotherapy alone
Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo
This strategic collaboration represents the third clinical trial under Senhwa’s five-year NCI-sponsored cancer research program
Cagrilintide represents a novel approach to obesity management
Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
Collaboration reinforces Boehringer Ingelheim’s expertise in microbial contract development and manufacturing
Rocket will also collaborate with investigators to implement an immunomodulatory regimen more closely reflecting that administered in the Phase 1 pediatric cohort
Subscribe To Our Newsletter & Stay Updated